Predictors of Parkinson's Disease Progression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-15

Study Completion Date

2024-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

it is a prospective longitudinal observational study, aiming to to identify clinical, and biochemical baseline predictors of motor and non-motor PD progression in sample of Egyptian patients. it measures the baseline motor, non-motor, biochemical and imaging characteristics at enrollment and its relation to PD progression over 3 years

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Determining Clinical Profile of Parkinson's Disease Among Egyptian Population

NCT02785510

Parkinson's Disease

UNKNOWN

Study for the Early Diagnosis of Parkinson's Disease

NCT02283073

Parkinson's Disease, Idiopathic

UNKNOWN

Comparison Between Parkinson's Disease and Parkinson's Dementia Complex (Genetically,Clinical and Electrophysiological)

NCT05759403

Parkinson Disease Dementia Parkinson Disease

UNKNOWN

Biomarkers in Parkinsonian Syndromes

NCT06501469

Parkinson Disease Progressive Supranuclear Palsy Multiple System Atrophy +2 more

RECRUITING

Differences Between Patients With Vascular Parkinsonism and Parkinson's Disease

NCT04308135

Vascular Parkinsonism Parkinson's Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

it is a prospective longitudinal observational study, aiming to to identify clinical, and biochemical baseline predictors of motor and non-motor PD progression in sample of Egyptian patients. it measures the baseline motor, non-motor, biochemical and imaging characteristics at enrollment and its relation to PD progression over 3 years.

The aim of this study is to identify clinical, and biochemical baseline predictors of motor and non-motor PD progression in sample of Egyptian patients.

Methods:

Assessment:-

Time • During the 2 years recruitment of patients from 2019 to 2021, the assessment will be at base line (first clinic visit), after 1yr, and after 2yrs.

Patients will be subjected to:

Clinical assessment:

* At base line, Patients will complete an extensive clinical evaluation, including:

1. Comprehensive medical history and neurological examination.
2. Demographic information (sex, age, education level, and occupation), as well as clinical characteristics of them (age at onset, duration of illness, received medications and doses).
3. Motor assessment; Movement Disorder Society (MDS) -Unified Parkinson's Disease Rating Scale (MDS-UPDRS) he motor portion (Part III) during OFF and ON states, Hoehn \& Yahr, and Schwab \& England scales.
4. Gait assessment, Gait will be assessed by:

Freezing of gait questionnaire Berg balance scale 10 m walk test Timed up and go test

Physical activity scale for elderly (PASE). Cognitive assessment; MOCA, MMSE. Cognitive assessment : during On state.
* All patients will be evaluated for global cognitive assessment by:
* Mini Mental State Examination (MMSE)Arabic version
* Montreal Cognitive Assessment (MoCA) Arabic version
* The standard battery included cognitive tests in the following domains: visuospatial skills, language, attention, executive functioning, and memory.

* Visuospatial skills will be assessed by clock drawing test and copy the intersecting pentagons of Addenbrooke's test (Arabic version)
* Language will be examined by Language similarity \& language subset of Addenbrooke's test (Arabic version)
* Attention will be evaluated by forward \&backward digit span tests and by the number of seconds needed to sequence numbers using a pencil (Trail making test A)
* For the evaluation of memory, participants will complete Wechsler memory subset, and investigators also will use their three-item recall from the MMSE.
* Executive functions will be measured by Wisconsin card sorting test and also Semantic verbal fluency test .

The non-motor symptoms scales (NMSS). Beck depression inventory (BDI). The Arabic version of The Parkinson's Disease Questionnaire (PDQ-39). Lab investigations MRI brain or CT brain . Serum alpha -Synuclein auto antibodies

All the following will be done at baseline, after 1 year, and after 2 year except, MRI brain and serum alpha-synuclein (only at baseline ).

This study will be approved from the ethical committee of Faculty of Medicine, Ain -Shams University.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Cognitive Dysfunction Biomarkers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

case group

patients diagnosed with idiopathic paaarkinson's disease according to the clinical criteria.

serum alpha synuclein autoantibodies, motor and non motor scales

Intervention Type DIAGNOSTIC_TEST

measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

serum alpha synuclein autoantibodies, motor and non motor scales

measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • All are Arabic-speaking individuals diagnosed with PD by a movement disorder neurologist based on the UK bank criteria for idiopathic Parkinson's disease.

* An oral informed consent will be taken from the cases before they participate in the study.

Exclusion Criteria

* Patients with red flag for being diagnosed with IPD and indicating secondary eg: vascular, Neuroleptics or atypical parkinsonism , progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration syndrome, Lewy body dementia

* Patients with with other comorbid chronic diseases
* PD patients who refused or could not complete questionnaires.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No